MaxCyte Inc (MXCT) News

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

MaxCyte Announces Retirement of Board Member Art Mandell

ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

MaxCyte to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...